64 181

Cited 11 times in

Prognostic significance of tetraspanin CD151 in newly diagnosed glioblastomas.

DC Field Value Language
dc.contributor.authorLee, D-
dc.contributor.authorSuh, YL-
dc.contributor.authorPark, TI-
dc.contributor.authorDo, IG-
dc.contributor.authorSeol, HJ-
dc.contributor.authorNam, DH-
dc.contributor.authorKim, ST-
dc.date.accessioned2014-05-02T05:08:14Z-
dc.date.available2014-05-02T05:08:14Z-
dc.date.issued2013-
dc.identifier.issn0022-4790-
dc.identifier.urihttp://repository.ajou.ac.kr/handle/201003/9892-
dc.description.abstractBACKGROUND: Tetraspanin CD151 is a positive effector of cancer invasion and metastasis.



METHODS: We investigated the expression of CD151 by immunohistochemistry in 211 cases of grade I to IV gliomas. Additionally, we performed O6-methylguanin-DNA methyltransferase (MGMT) methylation analysis using real-time methylation-specific PCR in 36 patients with glioblastoma, and the prognostic significance of these biomarkers in glioblastomas was evaluated.



RESULTS: Overexpression of CD151 was observed in a significant proportion (55.6%) of glioblastomas, while CD151 was rarely overexpressed in most of grade I to III glial tumors. CD151 overexpression was closely associated with MGMT methylation (P = 0.014), and it was a prognostic factor for predicting worse overall survival (OS; P = 0.002) and progression-free survival (PFS; P = 0.043). We also found that combination of CD151 overexpression and MGMT methylation better stratified the patients' OS (P = 0.001) and PFS (P = 0.009). In multivariate analysis, CD151 overexpression was an independent prognostic factor for predicting OS over MGMT methylation (P = 0.012).



CONCLUSIONS: CD151 seems to have a critical role for high-grade progression in astroglial tumors. Furthermore, CD151 is a good tissue marker that can be used easily in a daily practice for predicting worse prognosis in patients with glioblastoma.
-
dc.language.isoen-
dc.subject.MESHAdult-
dc.subject.MESHAged-
dc.subject.MESHAntigens, CD151/*metabolism-
dc.subject.MESHBrain/surgery-
dc.subject.MESHBrain Neoplasms/genetics/*metabolism/mortality/therapy-
dc.subject.MESH*Cerebral Cortex-
dc.subject.MESHChemoradiotherapy, Adjuvant-
dc.subject.MESHDNA Methylation-
dc.subject.MESHFemale-
dc.subject.MESHFollow-Up Studies-
dc.subject.MESHGene Expression Regulation, Neoplastic-
dc.subject.MESHGlioblastoma/genetics/*metabolism/mortality/therapy-
dc.subject.MESHGlioma/genetics/metabolism/mortality/therapy-
dc.subject.MESHHumans-
dc.subject.MESHImmunohistochemistry-
dc.subject.MESHMale-
dc.subject.MESHMiddle Aged-
dc.subject.MESHMultivariate Analysis-
dc.subject.MESHO(6)-Methylguanine-DNA Methyltransferase/genetics-
dc.subject.MESHPrognosis-
dc.subject.MESHReal-Time Polymerase Chain Reaction-
dc.subject.MESHSurvival Analysis-
dc.subject.MESHTumor Markers, Biological/*metabolism-
dc.subject.MESHUp-Regulation-
dc.titlePrognostic significance of tetraspanin CD151 in newly diagnosed glioblastomas.-
dc.typeArticle-
dc.identifier.pmid22926763-
dc.contributor.affiliatedAuthor이, 다근-
dc.type.localJournal Papers-
dc.identifier.doi10.1002/jso.23249-
dc.citation.titleJournal of surgical oncology-
dc.citation.volume107-
dc.citation.number6-
dc.citation.date2013-
dc.citation.startPage646-
dc.citation.endPage652-
dc.identifier.bibliographicCitationJournal of surgical oncology, 107(6):646-652, 2013-
dc.identifier.eissn1096-9098-
Appears in Collections:
Journal Papers > School of Medicine / Graduate School of Medicine > Pathology
Files in This Item:
fulltext not available.txtDownload

qrcode

해당 아이템을 이메일로 공유하기 원하시면 인증을 거치시기 바랍니다.

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse